| Name | Title | Contact Details |
|---|---|---|
Mark Finkle |
VP of Engineering (Productivity & Developer Program) | Profile |
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson`s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome. And in early-stage clinical research, we are exploring novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. Important Notice for Candidates - Be Aware of Fraudulent Recruiting Activity Acadia Pharmaceuticals has become aware of fraudulent recruiting activity being circulated via email and LinkedIn by individuals impersonating Acadia Talent Acquisition employees. These communications may appear legitimate due to an official-looking Acadia email address or website, referencing of an actual recruiter and/or manager at Acadia (easily found on LinkedIn), and/or offer documents falsely signed by an Acadia executive. The impostor uses the incentive of a job interview and job offer to solicit sensitive personal information from the intended victim. Please note that the Acadia Talent Acquisition and HR Team will ONLY interact with a candidate from "Acadia-pharm.com" domain sourced emails. We do not request sensitive personal information, such as a Social Security Number, or payments of any kind during the interview or job offer process. Acadia strongly recommends individuals, who receive email solicitations, to carefully verify the authenticity of the correspondence before responding. Never provide personal information or click on links if you are unsure a communication`s legitimacy. If in doubt, please contact talentacquisition@acadia-pharm.com to verify.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.
Lutherwood is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Universal Hospital Services, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about Universal Hospital Services, Inc., please visit www.uhs.com
HelixVM is a cutting-edge digital health start-up revolutionizing the way healthcare is delivered. Our goal is to free both physicians and patients from the repetitive and time-consuming aspects of routine care, while simultaneously increasing patient access to care and physician income. We understand that the largest healthcare issue today is the challenge of increasing capacity without increasing providers. That`s why we`ve developed innovative solutions that utilize technology to streamline the treatment process and optimize resource allocation. By harnessing the power of asynchronous medicine and AI, we are able to provide patients with fast and efficient access to care, while also freeing up physician time to focus on more complex and critical cases. At HelixVM, we believe that by empowering patients and providers with the tools they need to deliver and receive high-quality care, we can help to transform the healthcare industry. Whether you`re a physician looking for a more efficient and rewarding way to practice medicine, or a patient seeking convenient and accessible care, we are here to help. Join us on our mission to revolutionize healthcare delivery and improve patient outcomes.